ExodusPoint Capital Management LP Makes New $1.06 Million Investment in Harrow, Inc. (NASDAQ:HROW)

ExodusPoint Capital Management LP purchased a new position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 31,447 shares of the company's stock, valued at approximately $1,055,000. ExodusPoint Capital Management LP owned 0.09% of Harrow as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock worth $10,717,000 after purchasing an additional 194,480 shares during the period. Trexquant Investment LP increased its stake in shares of Harrow by 1,806.8% in the 4th quarter. Trexquant Investment LP now owns 94,500 shares of the company's stock valued at $3,170,000 after purchasing an additional 89,544 shares in the last quarter. Barclays PLC lifted its position in shares of Harrow by 301.9% during the 3rd quarter. Barclays PLC now owns 52,593 shares of the company's stock valued at $2,365,000 after buying an additional 39,506 shares in the last quarter. Diametric Capital LP raised its position in shares of Harrow by 49.0% during the 4th quarter. Diametric Capital LP now owns 110,295 shares of the company's stock worth $3,700,000 after purchasing an additional 36,269 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Harrow in the third quarter valued at approximately $1,469,000. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Price Performance

Shares of NASDAQ HROW traded down $0.53 during trading on Wednesday, hitting $23.26. 41,229 shares of the company were exchanged, compared to its average volume of 507,364. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a 1 year low of $9.86 and a 1 year high of $59.23. The company has a market cap of $829.31 million, a price-to-earnings ratio of -24.74 and a beta of 0.46. The firm's fifty day moving average price is $26.59 and its 200 day moving average price is $36.08.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. The firm had revenue of $66.83 million during the quarter, compared to the consensus estimate of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, sell-side analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on HROW. HC Wainwright restated a "buy" rating and issued a $57.00 target price on shares of Harrow in a report on Monday, March 31st. B. Riley dropped their target price on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.